This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Viral Infections  • Dermatology  • Dermatologic Disorders  • Psoriasis  • Drug Therapy  • Adverse Effects  • Infectious Diseases  • Alert me on articles by topic  Social Bookmarking   What's this?

F. Javier Miquel, MD; Javier Colomina, PhD; Juan I. Maríi, MD; Carmen Ortega, MD

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Cytomegalovirus (CMV) is characterized by lifelong latent infection following primary infection. Prevalence of viral carriage in adult populations is high. Infections with CMV in immunocompetent persons are usually asymptomatic, but in the immunocompromised patient, primary infection or reactivation of latent infection may be severe.

Efalizumab is a humanized monoclonal antibody that blocks lymphocyte activation and migration. We describe herein a case of CMV infection occurring in a patient with psoriasis who was undergoing efalizumab therapy.

Report of a Case

Our patient was a 53-year-old man with severe palmoplantar psoriasis of 6 years' duration. He was otherwise in good health and was not taking any medication. Topical psoriasis treatments had been ineffective, and we began treating him with acitretin. He showed significant improvement, but the adverse effects were intolerable, so the acitretin therapy was discontinued.

We then considered biological therapy with . . . [Full Text of this Article]

Comment

AUTHOR INFORMATION


CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?